The ELN Foundation is a non-profit charitable organization that to supports the EuropeanLeukemiaNet (ELN) to make all types of leukemia curable diseases.
The ELN Foundation is a non-profit charitable organization that was created to support the EuropeanLeukemiaNet (ELN) to make all types of leukemia curable diseases.
What is the ELN?
The ELN is an established network of excellence in leukemia research and treatment, composed of internationally recognised clinicians and scientists, medical study groups and interdisciplinary research centers reaching across four continents (Europe, North America, Asia and Australia).
The ELN has a landmark history of enabling the best therapeutic options to leukemia patients.
Rapid exchange of novel research data and treatment outcome has set milestones in the survival and quality of life of leukemia patients worldwide.
More than 100.000 patients are diagnosed with leukemia in Europe each year and about 45.000 within the US. Many lives are affected and the cost to society is significant. The challenge is to improve survival of patients.
Below you find a picture of the ELN participants at the Annual ELN Symposium 2010 in Mannheim, Germany
ELN Workpackages (WPs)
The ELN is a two layer networking organization, with a network level and a workpackage (WP) level, harbouring clinical trial groups for each leukemia and their interdisciplinary partners. The leadership of the workpackages is spread all over Europe.
For further information please have a look at the structure of the ELN and the participating countries.
ELN Projects and activities
A critical mass of patients is imperious in rare cancers and makes collaboration both necessary and attractive.
1) Concentrate leukemia excellence, know-how and resources:
The ELN has joined forces to
- avoid the duplication and fragmentation of clinical trials, to
- improve definitions and standards in diagnosis and therapy and to
- achieve a more complete registration of leukemia patients.
2) Get the best drugs: The ELN assesses and compares treatment options across Europe including combinations of drugs, dose escalation, state of the art transplantation technology and new agents.
3) Optimal treatment options: The collection of data in patient registries and of patient samples in a uniform and standardized manner will provide the information needed to develop and validate prognostic models for the different leukemic disease entities.
Further Information on the ELN
- The detailed Work Programme you find in the Activity Report for 2009 and the ELN Implementation Plan 2010-2011
- Picture of the Participants form the annual ELN symposium 2009 in Mannheim, Germany
- A map of participating countries and centers
- Further information on the ELN web site